MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ
1.780
-0.010
-0.56%
After Hours: 1.800 +0.02 +1.12% 19:59 05/22 EDT
OPEN
1.810
PREV CLOSE
1.790
HIGH
1.820
LOW
1.680
VOLUME
1.26M
TURNOVER
--
52 WEEK HIGH
4.555
52 WEEK LOW
1.480
MARKET CAP
121.70M
P/E (TTM)
-2.6731
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRDF last week (0518-0522)?
Weekly Report · 10h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (CRDF), ACADIA Pharmaceuticals (ACAD) and Immunic (IMUX)
TipRanks · 3d ago
Cardiff Oncology Reveals Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib In First-Line RAS-Mutated mCRC
Benzinga · 4d ago
Cardiff Oncology updates Phase 2 onvansertib data in first-line RAS-mutated mCRC trial
PUBT · 4d ago
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
Barchart · 4d ago
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense
Benzinga · 5d ago
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Cardiff Oncology (CRDF)
TipRanks · 5d ago
Cardiff Oncology Files Lawsuit Over Onvansertib Patent Rights
TipRanks · 5d ago
More
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company advancing cancer treatments focused on Polo-like Kinase 1 (PLK1) inhibition, a validated oncology target with practice-changing potential. The Company's lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor being evaluated in a Phase II trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML). The Company's clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.

Webull offers Cardiff Oncology Inc stock information, including NASDAQ: CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.